麦澜德(688273) - 投资者关系活动记录表（2024年6月3日业绩说明会）

Financial Performance - In 2023, the company achieved an operating income of 341 million RMB, a decrease of 9.57% year-on-year [2] - The net profit attributable to shareholders was 89.82 million RMB, down 26.19% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 71.54 million RMB, a decrease of 19.43% year-on-year [2] - As of December 31, 2023, total assets amounted to 1.534 billion RMB, an increase of 1.46% year-on-year [2] - The net assets attributable to shareholders were 1.346 billion RMB, a decrease of 0.33% year-on-year [2] Research and Development - R&D investment for 2023 was 58.24 million RMB, an increase of 40.89% year-on-year [2] - The total number of R&D personnel reached 140, a growth of 10.24% year-on-year [2] - The company submitted 55 patent and software copyright applications, including 24 invention patents [2] - A total of 29 new patents and software copyrights were authorized, with 7 being invention patents [2] Quarterly Performance - In Q1 2024, the company reported an operating income of 10.4 million RMB, a decrease of 4.39% year-on-year [2] - The net profit attributable to shareholders was 36.29 million RMB, an increase of 12.04% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 33.67 million RMB, up 24.67% year-on-year [2] - R&D investment in Q1 2024 totaled 12.95 million RMB, a year-on-year increase of 6.78% [3] Dividend Distribution - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares (tax included), totaling 59.33 million RMB [3] - The proposed cash dividend represents 66.06% of the net profit attributable to shareholders for 2023 [3] - The cash dividend payout ratio for the year is 86.62% [3] Market Position and Product Development - The company launched the "Magnetic Electric Thermal Imaging • Smart Integration PI-ONE" pelvic floor intelligent diagnosis and treatment system in March 2024 [4] - The product integrates pelvic structure and functional information, enhancing diagnostic accuracy and treatment efficiency [4] - The company is actively promoting the new product, with some hospitals already completing sales [4]